Tocilizumab biosimilar - Mycenax Biotech

Drug Profile

Tocilizumab biosimilar - Mycenax Biotech

Alternative Names: LusiNEX

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mycenax Biotech
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Juvenile rheumatoid arthritis; Rheumatoid arthritis

Most Recent Events

  • 09 Oct 2017 Tocilizumab biosimilar - Mycenax Biotech is available for licensing as of 09 Oct 2017. www.mycenax.com.tw
  • 09 Oct 2017 Therapeutic Goods Administration approves an application for initiation of a phase I trial (In volunteers) of tocilizumab biosimilar in Australia
  • 06 Oct 2017 Mycenax Biotech announces intention to submit a Clinical Trial Application for Rheumatoid arthritis and Juvenile rheumatoid arthritis in Europe in October 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top